Dopaminergic function in patients with posttraumatic parkinsonism: An 18F-dopa PET study
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Posttraumatic encephalopathy (PTE) is characterized by a combination of upper motor neuron, basal ganglia, cerebellar, and psychiatric disturbances. A "striatal" variant, with predominant posttraumatic parkinsonism (PTP), is uncommon and may be difficult to distinguish from idiopathic Parkinson's disease (PD). We report the clinical characteristics of six patients clinically presumed to have PTP who were investigated with 18F-dopa PET. We compared their findings with those of age-matched controls and a group of idiopathic PD patients without a history of head trauma. The PTP patients showed a uniform 40% reduction (p < 0.0001) of mean18 F-dopa uptake in caudate and putamen compared with controls. Their mean putamen uptake was significantly higher than that seen in the PD group(p < 0.004) while mean caudate uptake was lower. The PTP mean caudate:putamen Ki ratio (0.97) was similar to that of controls(1.10) but significantly lower than that of the PD group (1.90) (p< 0.0001). These results suggest that although PTP may appear clinically similar to PD, 18F-dopa PET may help to differentiate it in vivo by demonstrating uniform nigrostriatal involvement as opposed to relative sparing of caudate function. These data also provide support for the view that delayed neurologic sequelae may follow cumulative head trauma.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complicationsMatthias Löhle, Julia Mende, Martin Wolz et al.Neurology, December 30, 2015 -
Article
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma et al.Neurology, September 29, 2017 -
Views & Reviews
The role of radiotracer imaging in Parkinson diseaseB. Ravina, D. Eidelberg, J. E. Ahlskog et al.Neurology, January 24, 2005 -
Article
Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variantsLinda P. Oosterveld, John C. Allen, Jr., Ebonne Y.L. Ng et al.Neurology, August 26, 2015